What is Anacetrapib: Do CETP inhibitors to reduce LDL more than statins have a role in PAD; What about Ezetimibe; How low an LDL should we try to get
Kavita Sharma, MD, FACC
Diplomate, American Board of Clinical Lipidology
OhioHealth Heart and Vascular Physicians

Disclosures
• Speakers Bureau – Amgen and Akcea

Effects of Tocestrapib in Patients at High Risk for Coronary Events

Barter et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. NEJM. 2007; 357:2109-2122

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

Schwartz et al. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. NEJM. 2012; 367:2089-2099

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Cannon et al. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. NEJM. 2017; 376:1933-1942

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

Lincoff et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. NEJM. 2017; 377:13-23

The NEW ENGLAND JOURNAL of MEDICINE
SEPTEMBER 20, 2017
Vol. 377 \ No. 13

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
The HPS3/TIMI-55 REVEAL Collaborative Group
Approximately 8% of these patients had PAD.

5.5% of patients in the IMPROVE-IT trial had PAD.

RCTs of cholesterol-lowering drugs in high-risk patients confirm that LDL-C lowering produces marked reductions in ASCVD. This confirms the general principle that “lower is better” for LDL-C.